{"name":"Samsung Biologics","slug":"samsung-bio","ticker":"207940.KS","exchange":"KRX","domain":"samsungbiologics.com","description":"Samsung Biologics Co., Ltd. (Korean: 삼성바이오로직스) is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.","hq":"Incheon, South Korea","founded":2011,"employees":"5195","ceo":"John Rim","sector":"Biologics CDMO / Biosimilars","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":1449000,"stockChange":39000,"stockChangePercent":2.77,"marketCap":"$45.0B","metrics":{"revenue":3226909295.915932,"revenueGrowth":0,"grossMargin":55.2,"rdSpend":0,"netIncome":1174396591.180651,"cash":1085914661.6447043,"dividendYield":0,"peRatio":29.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"adalimumab patent cliff ($10.9B at risk)","drug":"adalimumab","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"rituximab patent cliff ($7.7B at risk)","drug":"rituximab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Samsung Biologics Reports Q4 2023 Earnings","summary":"Samsung Biologics reported its Q4 2023 earnings, with revenue of KRW 2.43 trillion and net income of KRW 1.15 trillion.","drugName":"","sentiment":"positive"},{"date":"2023-12-15","type":"deal","headline":"Samsung Biologics Partners with Biocon to Develop Biosimilars","summary":"Samsung Biologics partnered with Biocon to develop biosimilars for the global market.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"Samsung Biologics Receives FDA Approval for New Manufacturing Facility","summary":"Samsung Biologics received FDA approval for its new manufacturing facility in South Korea.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQekg5YXhHc1RKX3VEMUFFU2dJMUlpMTZPSV9ObG9qOWdBenpjT1VBQ25zbS1iYV9TcmszcVMxUUVnWDlvMDJaQ3RKak5kMGNzTFVyNUVyYzdVOTFDOXl4eWFxaGNOdW1JMVRMbEk5MXhkNm1HVDhjU25rZUtFNzcwLTV6LUM5SWdUTWlRWWk0YnRGcG9idnlIUUlTSQ?oc=5","date":"2026-04-05","type":"pipeline","source":"Seoul Economic Daily","summary":"Korea Discusses Response to U.S. Section 232 Tariffs on Pharmaceuticals - Seoul Economic Daily","headline":"Korea Discusses Response to U.S. Section 232 Tariffs on Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPanZtbkNSYjF0OHVzR3l1Rk9sUTh2YzFZc25hTjV1bjZVYzlwWC1ISVlzcmJrNlJOVTdBTmZYbU9HWThobGExYi1IM2xaTFVTX2swS1dJcWlHVkE5UHQyWnpXOEJRX2d4dElCeUdNZTR1MjFiYjBqanhXU0pmSDZRQlMxMnFBajdfaENHMkVpVXo1N1VnNFA2dnl2dmlEOFk?oc=5","date":"2026-04-02","type":"earnings","source":"Seoul Economic Daily","summary":"K-Pharma and Bio Firms' Combined Revenue Tops 30 Trillion Won in 2024 - Seoul Economic Daily","headline":"K-Pharma and Bio Firms' Combined Revenue Tops 30 Trillion Won in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOd2sxMDhhODc5UFlVeE9HMlBmLUtmWmNRWnU5RzVsemt1cWJVZGZNR2d5Z1k1TF9sb0pVaWZiMjVsUl9oUW85QzZMakp2dTlUY3pLdmlYeGpqZ3BKRVBtd0t0R2wyVzFrVGlaRzc5ZVFxRnJraERpeGk1VGFESk9WVEVOUlBXXzlpTnExSmxfQzd3MzUtZkw2VmZhVTBaQQ?oc=5","date":"2026-04-02","type":"earnings","source":"Seoul Economic Daily","summary":"K-Pharma and Bio Revenue Tops 30 Trillion Won on New Drugs, Exports - Seoul Economic Daily","headline":"K-Pharma and Bio Revenue Tops 30 Trillion Won on New Drugs, Exports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOS0RVRjVFaVNMbUxiRDRRNEV4Y2QzM0R5Nks3X3U2VXViSVpsXzVIUVFpRGZ2VXpFdVY4cGtLOERMUlBOYmlfckhTOHk4dURPTFhQWGdqcjhyd0xZQW53azQtb3FiWHZMYkp0Q2JsQzBfNHQ3MjM0clExaTlWTEdwQkhGWDNXMEZOeXBJRGp3YUxOTFNWT3dvSDIxemdHWUo5UjNPOW1oTFhaWWNDVWZRZUNETy1MVnNwSVJIYURCY2p5Y1I4T3k5dFlOTFU2YUo3bGhBYUFsWQ?oc=5","date":"2026-04-01","type":"pipeline","source":"BioPharma APAC","summary":"Samsung Biologics Completes Rockville Facility Acquisition To Expand U.S. Manufacturing Footprint - BioPharma APAC","headline":"Samsung Biologics Completes Rockville Facility Acquisition To Expand U.S. Manufacturing Footprint","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPMUdyQ3pEck43MnVNWFFtS3Y5SzhzNTNSX0xZeE9NR3llVDl3RXlUSm84NEd4eHpTMlB6cVRMWFI2WlJiak5zR2ZySnl4cEl1bl91MUxkTmJqcm5VeXBob3VaQnh6SXljYWpoYjF1Y3p4UkpXZXNQOTZOSTRqSDRXQkhSRnN3WWhKakhtNnZWYVRxUmwzMi1IQmhVanA?oc=5","date":"2026-03-30","type":"pipeline","source":"Seoul Economic Daily","summary":"Samsung Biologics Wins CDMO Leadership Awards for 13th Consecutive Year - Seoul Economic Daily","headline":"Samsung Biologics Wins CDMO Leadership Awards for 13th Consecutive Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUnZNalQ0YUxvQ2l1M19fV2hsWGFBbmlVUnRUSlViaERLYl95eU05V0h2dE8xVHZtYzFrZDVxWUY1TXcxUmFySUhjVG42cWNONUh5alI0eWswUmkwMWhzeFpmWS1lRUNjVkJSeTVFbUktUjZKQXpHa0pNTllyU21hUEhJQzhtWTJudEFqZVVhZC0xMWRLczVJMmprVUhnY0FmYjM1Z3F3Vzc?oc=5","date":"2025-12-21","type":"deal","source":"PharmaLive","summary":"Samsung Biologics to buy US drug production facility from GSK for $280 million - PharmaLive","headline":"Samsung Biologics to buy US drug production facility from GSK for $280 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQTDNVaHJBUmJIYnJWSG9HNGVZZ2ZDLW52RVg1akRkYkMtTk1iNWd3MTJCU01aQl9CMEpLOFBHYWdwLWNMYzZuWkYwbGc3QW9kNkFudGlCc1RLNVhldGdubmV6bnZ4cjhEc3BxM0NjMGxoel9oTGtXd2w4NmpBbTlxRTBNTGhBaVBXWkN5cW05Q1NsOXNaSmM3d2lUcFd3SFUtanpZT3RQRWZuc2N5QjhDU082RU01bS10emVTMXlCV1FpcDNnUVZnWjItMGFpUWZ2dHc?oc=5","date":"2025-11-03","type":"pipeline","source":"PR Newswire","summary":"Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO - PR Newswire","headline":"Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPWk1SOWRYOTdQNnB2c1V0Nnc2OE5zWUF3c19xTlFpVE01UC1LUVdTS2h3OUxHcUR4TUJXYlI3ajV4RWVxX3o5U2dBV1JDRDNHOVl6ZEtQaXB6eWpDbHFvOExRNm1MS3BXZ0dkQmdpWkM5dFMtQkRmbmc4VzEzTVdjRFZGSEtWenlqdzRwNWV2eXluUTNVNkJBXzU0T3dVNUVWRlNTcHVYNUpFQTFmUjlZeGhwamdURk1tNWozQU1GbDFBZFJIMWF4Y2o3UTY5aGgxU1pYMktMZw?oc=5","date":"2025-01-23","type":"pipeline","source":"BioPharma APAC","summary":"Samsung Biologics Eyes Growth in 2025 with New Plant, ADC Services, and Sustainability Investments - BioPharma APAC","headline":"Samsung Biologics Eyes Growth in 2025 with New Plant, ADC Services, and Sustainability Investments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQNGR6QzA1cENVNjZZSjdMcDlHWHpBVkgzRWhXeEJiWWEtQlAwTWFtanF2SXJvXzYwNzFkQ3pDaktTWm1UOXprckxybThOMmtpejkzQUpEV0NibU1FWVB5RDhWbUlpSG0xTk9EbHVWUklZUTFQMEd5cjQ3NDR0X21qaWNma1hCUUh4bnRUNV9VTWtsUW5kWGFVWmNWMnR5TEhZYjVGTVRrRjZHbW0ycXRmel9zUVFONUQtSTRfYWJpN0N3Vkd2aVVoVUVsQVhXYm5Y?oc=5","date":"2024-11-19","type":"deal","source":"PR Newswire","summary":"Samsung Biologics signs manufacturing deal with European pharmaceutical company - PR Newswire","headline":"Samsung Biologics signs manufacturing deal with European pharmaceutical company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNWnpOMThtZ3hiZmhCTUQwWjh3bVkzRTlSMnIwdVZvaVJwNHJHa3BDYmozMnEteE1HY0FOdDR2Nm45TlhmOGlJLVNPd1ZSNTgtNDV5bUVnUFpmZFRrSG5kUlFuOHpHVVZmS3NmRWhmQmdieHFxM2M5UjBldXJyaHNqMGJqWGk2NjlOcGltTG5tZDNKb2E2bUgwdHppY1RTd2JHaFhYSlB1X1lIenRVWkhCTTd1ME9VZ29tMk4zRkFiRC1mcjNPb0dV?oc=5","date":"2024-10-22","type":"pipeline","source":"BioPharma APAC","summary":"Samsung Biologics Inks $1.24 Billion Manufacturing Agreement with Leading Asia Pharma - BioPharma APAC","headline":"Samsung Biologics Inks $1.24 Billion Manufacturing Agreement with Leading Asia Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOS1MyTUNPak1TS0NCYzlGSWk0UF9majB0bGhXR19TWlpBRzEweHlMRFhocDJNZjVveko2S2hSVzVRYTRTM01pUEExemdyd19xWjlxMGF4akJlc3IwOXVvZ1MycU1kY1pLRjFpVE5zVXU2STJUZlE0MlpqaWNhUVN1VWNCdnBFbzVnaTdzVHgzU0IwcVNmcjN0eFFqTklHS05vQUJ0c2FMM2VTRnQ3dmpyS3JYeFExS190cDRyN25HV1pGR0ZxanJCVVJiQUw5TklZSWg0ZjlIRWxHNG56ZHc?oc=5","date":"2024-10-21","type":"deal","source":"PR Newswire","summary":"Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company - PR Newswire","headline":"Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company","sentiment":"neutral"}],"patents":[{"drugName":"rituximab","drugSlug":"rituxan","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":7700000000},{"drugName":"adalimumab","drugSlug":"humira","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10900000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":6,"keyCompetitors":["Catalent","Lonza","Pfizer"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":{"source":"yahoo_finance","revenue":3054618785.6781588,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":3054618785.6781588},{"period":"2024-12-31","value":2344198645.9537954},{"period":"2023-12-31","value":2476548244.781495},{"period":"2022-12-31","value":2011821293.929903}],"grossProfit":1686948612.4642813,"grossProfitHistory":[{"period":"2025-12-31","value":1686948612.4642813},{"period":"2024-12-31","value":1147037392.419409},{"period":"2023-12-31","value":1208424994.365422},{"period":"2022-12-31","value":984326707.929427}],"rdSpend":24923229.960735302,"rdSpendHistory":[{"period":"2025-12-31","value":24923229.960735302},{"period":"2024-12-31","value":24607905.965651374},{"period":"2023-12-31","value":54689872.195660524},{"period":"2022-12-31","value":30756687.7564219}],"sgaSpend":113708189.19483028,"operatingIncome":1387035640.2921338,"operatingIncomeHistory":[{"period":"2025-12-31","value":1387035640.2921338},{"period":"2024-12-31","value":885735273.1413357},{"period":"2023-12-31","value":746519422.7185199},{"period":"2022-12-31","value":659342852.9527344}],"netIncome":1196082769.2449496,"netIncomeHistory":[{"period":"2025-12-31","value":1196082769.2449496},{"period":"2024-12-31","value":726165813.0635759},{"period":"2023-12-31","value":574925658.4400954},{"period":"2022-12-31","value":534951203.2115424}],"eps":15221,"epsHistory":[{"period":"2024-12-31","value":15221},{"period":"2023-12-31","value":12051},{"period":"2022-12-31","value":11432},{"period":"2021-12-31","value":5886.514647}],"cash":99777638.61577341,"cashHistory":[{"period":"2025-12-31","value":99777638.61577341},{"period":"2024-12-31","value":262242774.63178447},{"period":"2023-12-31","value":246634928.2776732},{"period":"2022-12-31","value":597132125.7130955}],"totalAssets":7414211122.20214,"totalLiabilities":2419599770.202676,"totalDebt":621447825.1714972,"equity":4994611351.999464,"operatingCashflow":1506745104.207915,"operatingCashflowHistory":[{"period":"2025-12-31","value":1506745104.207915},{"period":"2024-12-31","value":1112228265.2236252},{"period":"2023-12-31","value":1116902470.1660616},{"period":"2022-12-31","value":638844816.0428624}],"capex":-988767886.0934045,"capexHistory":[{"period":"2025-12-31","value":-988767886.0934045},{"period":"2024-12-31","value":-923379747.5952296},{"period":"2023-12-31","value":-740918685.8621383},{"period":"2022-12-31","value":-676501790.3466147}],"freeCashflow":517977218.11451054,"dividendsPaid":null,"buybacks":-61677616.52108661,"employees":5195,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":-96870712.20601213,"ebit":297367290.4747945,"ebitda":373193511.2859462,"period":"2025-12-31","revenue":206841608.89214382,"epsBasic":null,"netIncome":341830284.842666,"rdExpense":-48730568.954975925,"epsDiluted":null,"grossProfit":57632848.452204056,"operatingIncome":253436886.37070346},{"sga":74307364.51838157,"ebit":521313763.7267682,"ebitda":641246661.5379194,"period":"2025-09-30","revenue":1112875403.7732656,"epsBasic":12409.452586,"netIncome":385070518.93676805,"rdExpense":22979036.84372066,"epsDiluted":12409.452586,"grossProfit":656133159.7568332,"operatingIncome":488559806.51466924},{"sga":65686117.339047275,"ebit":279634336.72075456,"ebitda":399082954.85573924,"period":"2025-06-30","revenue":864646435.2970821,"epsBasic":4558,"netIncome":217441772.97928497,"rdExpense":27030691.904122908,"epsDiluted":4558,"grossProfit":481949065.0317861,"operatingIncome":318802880.9102525},{"sga":70585419.48308498,"ebit":341394663.45460755,"ebitda":450924966.9995967,"period":"2025-03-31","revenue":870255337.7156674,"epsBasic":5277,"netIncome":251740192.4862305,"rdExpense":23644070.16116448,"epsDiluted":5277,"grossProfit":491233539.22345805,"operatingIncome":326236066.6104626},{"sga":121778783.74974953,"ebit":266843229.12277246,"ebitda":367938894.38162684,"period":"2024-12-31","revenue":842213429.6461288,"epsBasic":null,"netIncome":215502859.85424557,"rdExpense":42817615.77680578,"epsDiluted":null,"grossProfit":448274670.8967896,"operatingIncome":218298289.8877126},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":3716,"netIncome":null,"rdExpense":null,"epsDiluted":3716,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1449000,"previousClose":1410000,"fiftyTwoWeekHigh":1987000,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"0.0 - 1987000.0","fiftyDayAverage":1557080,"twoHundredDayAverage":1665652.5,"beta":0.26,"enterpriseValue":121613561930.2564,"forwardPE":29.9,"priceToBook":0,"priceToSales":13.93,"enterpriseToRevenue":37.69,"enterpriseToEbitda":0,"pegRatio":3.24,"ebitda":0,"ebitdaMargin":0,"freeCashflow":0,"operatingCashflow":0,"totalDebt":616021959.7791494,"debtToEquity":11.6,"currentRatio":1.7,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":25,"targetMeanPrice":2163528.8,"targetHighPrice":2613811,"targetLowPrice":1650000,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":74.4,"institutionHeldPercent":15.6,"sharesOutstanding":46290951,"floatShares":33010332,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":68003.98,"bookValue":0,"officers":[{"age":64,"name":"Mr. John Chongbo  Rim","title":"CEO, President & Chairman of Board"},{"age":62,"name":"Dr. Kun  Lo Ph.D.","title":"Executive VP, Head of EPCV Center & Director"},{"age":57,"name":"Mr. Seung ho  Ryu","title":"EVP, CFO, Head of Business Support Center & Director"},{"age":57,"name":"Mr. Pierre  Catignol","title":"Executive VP & Head of Operation Center"},{"age":null,"name":"Mr. Kevin  Sharp","title":"EVP, Head of Sales & Operations Department"},{"age":null,"name":"Mr. Kyuho  Lee","title":"Executive VP, Head of People Center, & Chief Human Resource Officer"},{"age":58,"name":"Mr. James J.  Choi","title":"Executive VP, Head of CDO Development Center & Head of Sales Center"},{"age":50,"name":"Mr. Heekyun  Lim","title":"VP & Head of Business Consulting Team"}],"industry":"Biotechnology","irWebsite":"","website":"https://samsungbiologics.com","phone":""}}